α-Eleostearic Acid as a Senolytic Therapy - Quick Reference Sheet
evipedia.aidev
← Back

α-Eleostearic Acid as a Senolytic Therapy

Created on 08/12/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 – Audit

α-Eleostearic acid is a seed fatty acid studied as a candidate that clears aging cells via iron-linked membrane damage. Evidence is laboratory-only: cells and mice show selective clearance and some aging-symptom gains, especially with a more selective lab form. No human trials of purified compound exist; seed oils carry stomach and reproductive cautions. (Full Review)

Protocol

Dose (experimental)
~200–350 mg/day
Scaled from ~50 mg/kg mouse; 3–5 day pulses; unvalidated in humans
Form
Methyl ester when available
More selective and sustained in cell studies; free acid more potent/faster
Schedule
Intermittent pulses
3–5 consecutive days per course, or thrice-weekly intermittent
Time to effect
Cell clearance
12–48 hours
Laboratory senescent-cell killing window
Tissue markers (mice)
Days after course
After 3–5 day short courses
Human function
Unmeasured
No human outcome timelines established

Benefits

Contraindications
  • Pregnancy or active attempts to conceive (seed-product reproductive toxicity signals)
  • Breastfeeding (insufficient safety data for concentrated α-eleostearic acid)
  • Children and adolescents (no senolytic dosing data)
  • Active peptic ulcer or severe uncontrolled GI disease (oil intolerance risk)
  • Known allergy to Cucurbitaceae (bitter melon) products
  • Significant iron overload disorders until specialist review (theoretical ferroptosis risk)
    •
Key Interactions
  • Iron supplements and IV iron (caution)
  • Strong antioxidants / high-dose vitamin E tocotrienols (caution)
  • Other senolytics (dasatinib, navitoclax, fisetin combinations) (monitor)
  • Antidiabetic drugs (insulin or sulfonylureas with crude melon seed products) (monitor)
  • Anticoagulants / antiplatelets (warfarin, apixaban, aspirin, clopidogrel) (monitor)
  • Hepatotoxic drugs (high-dose acetaminophen, methotrexate, isoniazid) (caution)
    •

Risk & Side Effects

  • High:
  • Medium: Gastrointestinal intolerance; reproductive and developmental concerns with crude seed products; hypoglycemia with crude bitter melon products
    •
  • Low: Off-target ferroptosis or cytotoxicity at high free-acid exposure; hepatic and metabolic stress from high-dose seed extracts
    •
  • Speculative: Interaction with iron overload or ferroptosis-sensitizing drugs; unknown long-term effects of repeated senolytic ferroptosis cycles
    •

Monitoring

Marker Target Why
ALT / AST ALT ~10–25 U/L; AST ~10–25 U/L Detect hepatic stress from oils or co-toxins
Ferritin Often ~50–150 ng/mL mid-range (context-dependent) Iron stores modulate ferroptosis risk/efficacy
CBC with differential Within age/sex lab norms; stable hemoglobin and neutrophils Watch cytopenias from off-target cytotoxicity
hs-CRP Often <1.0 mg/L Crude systemic inflammation surrogate
Fasting glucose or HbA1c Glucose ~70–90 mg/dL fasting; HbA1c individualized Melon-seed products may alter glycemia

Cadence: Baseline before use; recheck safety labs within 3–7 days after each multi-day pulse, then every 3–6 months if cycling continues

Qualitative Assessment

  • GI tolerance
  • Energy stability
  • Exercise recovery
  • Joint comfort
  • Sleep continuity
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.